Search 

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

apceth is a privately held German Biotech company focused on the development and clinical implementation of innovative biopharmaceuticals based on cell and gene therapy in the field of oncology.

Enabling platform technology for genetic modification of mesenchymal stem cells (MSC) to be used as drug shuttle to target tumors or other areas of interest.

Clinical development:

phase I with modified MSC in gastro-intestinal tumors completed (12/2014)

phase I/II with MSC for vascular disease completed

strong clinical pipeline based on genetic modification of MSC

Implementation of allogeneic cell bank system to accomodate off-the-shelf production of cell-based pharmaceuticals.

Strong network and IP,

interesting preclinical pipeline addressing oncology, lung disease, inflammation.

Secure financing by German Family Offic. Looking for partner/ cofinancing for ongoing clinical development (phase II/III)

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.

Armune BioScience is a medical diagnostics company formed to develop and commercialize unique technology for diagnostic and prognostic tests for prostate, lung and breast cancers. The technology is unique because it utilizes autoantibodies created by the body’s own immune system to detect cancer at an early stage. When the immune system recognizes a cancer antigen it creates an autoantibody to the antigen which is replicated by the immune system. Armune’s technology can be used to detect these autoantibodies in serum.

Early detection and prognosis of cancer is critical not only in selecting appropriate treatment protocols, but also in increasing 5-year survival rates among cancer patients. Cancer detection in early stages is typically performed by detecting cancer-specific serum antigens. Unfortunately, cancer serum antigens are present at very low levels in early stage disease. Also, a single detectable cancer antigen may not be present in all patients due to heterogeneity of the disease and therefore multiple biomarkers are needed. Detection of serum autoantibody responses to tumor antigens provides more reliable serum marker(s) for cancer diagnosis. Serum autoantibodies are more stable than serum antigens and may be more abundant than antigens, especially at low tumor burdens characteristic of early stage cancer. The technology does not detect cancer per se, but looks for the immune response to cancer.

Armune’s initial focus is on a prostate cancer diagnostic test. The PSA (Prostate Specific Antigen) test is currently used as a prostate cancer diagnostic test and it has good sensitivity (~86%), but very poor specificity (20 to 30%) resulting in high false positive rates (70 to 80%) and many unnecessary biopsies and costs.